Editorial Advisory Board

This activity is supported by an educational grant from Teva Neuroscience.

Target Audience

This activity has been designed to meet the educational needs of physicians involved in the management of patients with Parkinson’s disease (PD).

Statement of Need/ Program Overview

Parkinson’s disease patients report that changes to their cognitive performance are particularly distressing. To meet the needs of their patients, physicians can determine the extent and type of intellectual decrements (eg, executive function, memory, or attention) by administering various task-based screens. Should these suggest cognitive problems, the treatment and management of cognitive dysfunction can be pursued. New insights into therapies that restore depleted neurotransmitter levels thereby improving cognition will help physicians target their recommendation to temper any cognitive deficits in Parkinson’s patients.

Educational Objectives

After completing this activity, the participant should be able to 1) Describe the neuropathology of the effect of cognitive impairment in Parkinson’s disease (PD), 2) Compare the different types of cognition affected by PD, 3) Compare the treatment and management options for cognitive decline in patients with PD.

Faculty

The members of the Neura editorial advisory board who have reviewed this content, as well as the other content featured in this issue, are listed above.

Accreditation Statement

This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Postgraduate Institute for Medicine and Expert Medical Education. The Postgraduate Institute for Medicine is accredited by the ACCME to provide continuing medical education for physicians.

Credit Designation

The Postgraduate Institute for Medicine designates this enduring material for a maximum of 0.75 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Conflict of Interest

Postgraduate Institute for Medicine (PIM) assesses conflict of interest with its instructors, planners, managers, and other individuals who are in a position to control the content of CME activities. All relevant conflicts of interest that are identified are thoroughly vetted by PIM for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. PIM is committed to providing its learners with high quality CME activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of a commercial interest.

The Neura Editorial Board members have reported their financial relationships or relationships to products or devices they or their spouses or life partners have with commercial interests related to the content of this CME activity. These disclosures are listed below.

The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity.

The following PIM planners and managers, Jan Hixon, RN, BSN, MA, Trace Hutchison, PharmD, Julia Kimball, RN, BSN, Samantha Mattiucci, PharmD, Jan Schultz, RN, MSN, CCMEP, and Patricia Staples, MSN, NP-C, CCRN hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

The following Expert Medical Education staff members, Melissa Carter-Özhan, Anneke Schwob, and Jennifer L. Shoemaker, PhD, hereby state that they or their spouse/life partner do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this activity of any amount during the past 12 months.

This publication contains reports of medical practices and investigations as presented at professional scientific meetings. This publication may include discussion of investigational uses of drugs, devices, and techniques that have not been recognized as safe and efficacious by the Food and Drug Administration and investigational uses of drugs, devices, and techniques that have been approved for other uses. In weighing the benefits of treatment against the risks, physicians should be guided by clinical judgment. Dosages, indications, and methods for the use of drugs, devices, and techniques referred to herein reflect data presented at professional scientific meetings in abstract, oral, or poster format and the clinical experience and discretion of the presenting investigators and/or authors. Consult complete prescribing information (drugs) and instructions for use (devices) before administering any of the agents discussed herein.

The editors have the following relationships to disclose.

PATRICIA K. COYLE, MD: Consulting fees: Acorda Therapeutics, Biogen Idec, Bayer Healthcare, EMD Serono, Novartis, Questor, Sanofi-Aventis, Teva Neuroscience/Teva Pharmaceutical Industries; Speakers’ bureaus: Bayer Healthcare, Biogen Idec; Contracted Research: Actelion, Novartis, Sanofi-Aventis.

PAUL S. FISHMAN, MD, PhD: Consulting fees: Allergan, Boehringer Ingelheim, Merz Pharma, Teva Neuroscience.

COREY C. FORD, MD, PhD: Consulting fees: Biogen Idec, EMD Serono, Novartis, ONO Pharmaceutical Company, Sanofi-Aventis, Teva Neuroscience/Teva Pharmaceutical Industries; Research Support: Biogen Idec, Elan, EMD Serono, Genzyme, Janssen, Novartis, Ono Pharmaceutical Company, Roche, Sanofi-Aventis, Teva Neuroscience/Teva Pharmaceutical Industries.

EDWARD J. FOX, MD, PhD: Consulting fees: Bayer Healthcare, Biogen Idec, EMD Serono, Genzyme, Opexa Therapeutics, Inc, Teva Neuroscience/Teva Pharmaceutical Industries; Speakers’ bureaus: Bayer Healthcare, Biogen Idec, EMD Serono, Novartis, Pfizer, Teva Neuroscience/Teva Pharmaceutical Industries; Contracted Research: Biogen Idec, Eli Lilly, EMD Serono, Genzyme, ONO Pharmaceutical Company, Roche, Sanofi-Aventis, Teva Neuroscience/Teva Pharmaceutical Industries.

ANDREW D. SIDEROWF, MD: Consulting fees: Teva Neuroscience/Teva Pharmaceutical Industries; Research Support: Avid Radiopharmaceuticals, Inc.

ANTHONY TRABOULSEE, MD: Consulting fees: Merck Serono, Roche; Speakers’ bureaus: Bayer Healthcare, Biogen Idec, EMD Serono, Teva Neuroscience/Teva Pharmaceutical Industries; Contracted Research: Bayer Healthcare, Biogen Idec, Canadian Institutes of Health Research, MS Society of Canada.

Members of the Neura Editorial Board receive honoraria for their service and contribution.

Method of Participation and Request for Credit

There are no fees for participating and receiving CME credit for this activity. During the period January 27, 2012, through January 27, 2013, participants must read the learning objectives and faculty disclosures and study the educational activity.

PIM supports Green CME by offering your Request for Credit online. If you wish to receive acknowledgment for completing this activity, please complete the post-test and evaluation on www.cmeuniversity.com. On the navigation menu, click on “Find Post-test/Evaluation by Course” and search by course ID 7977. Upon registering and successfully completing the post-test with a score of 70% or better and the activity evaluation, your certificate will be made available immediately. Processing credit requests online will reduce the amount of paper used by nearly 100,000 sheets per year.

Media

Journal supplement

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Postgraduate Institute for Medicine (PIM), Expert Medical Education, and Teva Neuroscience do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of PIM, Expert Medical Education, and Teva Neuroscience. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Readers: Correspondence and inquiries may be addressed to Expert Medical Education, 1875 Eye Street, NW, Suite 900, Washington, DC 20006, faxed to 202-326-1823, or e-mailed to Neura@expertmeded.net.

Neura: Perspectives on CNS Disease Management is supported by an educational grant from Teva Neuroscience and is published by Expert Medical Education, 1875 Eye Street, NW, Suite 900, Washington, DC 20006.

The opinions herein do not reflect those of the editorial board of Neura: Perspectives on CNS Disease Management, Expert Medical Education, or Teva Neuroscience. On all matters of pertinent coverage, the editorial board’s decisions are final.

Copyright © 2012 Expert Medical Education. All rights reserved.